blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2994470

EP2994470 - PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS [Right-click to bookmark this link]
Former [2016/11]QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
[2017/45]
StatusNo opposition filed within time limit
Status updated on  22.02.2019
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  16.03.2018
FormerGrant of patent is intended
Status updated on  30.10.2017
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Principia Biopharma Inc.
400 East Jamie Court, Suite 302
So. San Francisco, California 94080 / US
[2016/11]
Inventor(s)01 / BRAMELD, Kenneth A.
345 Camino Al Lago
Meno Park, California 94002 / US
02 / VERNER, Erik
1521 Notre Dame Ave.
Belmont, California 94002 / US
 [2016/11]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2018/16]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2016/11]Srinivasan, Ravi Chandran
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date14730018.007.05.2014
[2016/11]
WO2014US37173
Priority number, dateUS201361821468P09.05.2013         Original published format: US 201361821468 P
[2016/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014182829
Date:13.11.2014
Language:EN
[2014/46]
Type: A1 Application with search report 
No.:EP2994470
Date:16.03.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.11.2014 takes the place of the publication of the European patent application.
[2016/11]
Type: B1 Patent specification 
No.:EP2994470
Date:18.04.2018
Language:EN
[2018/16]
Search report(s)International search report - published on:EP13.11.2014
ClassificationIPC:C07D471/04, A61K31/519, A61P35/00
[2016/11]
CPC:
C07D471/04 (EP,US); A61P35/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/11]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PYRIDO[2,3-D]PYRIMIDIN-DERIVATE ALS INHIBITOREN DES FIBROBLASTENWACHSTUMSFAKTORS[2017/45]
English:PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS[2017/45]
French:DÉRIVÉS DE PYRIDO[2,3-D]PYRIMIDINE EN TANT QU' INHIBITEURS DE FACTEUR DE CROISSANCE DE FIBROBLASTE[2017/46]
Former [2016/11]CHINOLONDERIVATE ALS FIBROBLASTEN-WACHSTUMSFAKTORINHIBITOREN
Former [2016/11]QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
Former [2016/11]DÉRIVÉS DE QUINOLONE À UTILISER EN TANT QU'INHIBITEURS DE FACTEUR DE CROISSANCE DES FIBROBLASTES
Entry into regional phase04.12.2015National basic fee paid 
04.12.2015Designation fee(s) paid 
04.12.2015Examination fee paid 
Examination procedure04.12.2015Examination requested  [2016/11]
29.06.2016Amendment by applicant (claims and/or description)
15.12.2016Despatch of a communication from the examining division (Time limit: M06)
23.06.2017Reply to a communication from the examining division
31.10.2017Communication of intention to grant the patent
09.03.2018Fee for grant paid
09.03.2018Fee for publishing/printing paid
09.03.2018Receipt of the translation of the claim(s)
Opposition(s)21.01.2019No opposition filed within time limit [2019/13]
Fees paidRenewal fee
27.05.2016Renewal fee patent year 03
30.05.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.05.2014
AL18.04.2018
AT18.04.2018
CY18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
MK18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
TR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
IS18.08.2018
PT20.08.2018
[2020/33]
Former [2020/31]HU07.05.2014
AL18.04.2018
AT18.04.2018
CY18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
MK18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
TR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2020/30]HU07.05.2014
AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
TR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2020/16]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
TR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2020/08]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/26]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SI18.04.2018
SK18.04.2018
SM18.04.2018
IE07.05.2018
LU07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/24]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SK18.04.2018
SM18.04.2018
IE07.05.2018
LU07.05.2018
BE31.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/19]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SK18.04.2018
SM18.04.2018
IE07.05.2018
LU07.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/17]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SK18.04.2018
SM18.04.2018
LU07.05.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/11]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
IT18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SK18.04.2018
SM18.04.2018
CH31.05.2018
LI31.05.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/10]AL18.04.2018
AT18.04.2018
CZ18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
MC18.04.2018
NL18.04.2018
PL18.04.2018
RO18.04.2018
RS18.04.2018
SE18.04.2018
SK18.04.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/09]AL18.04.2018
DK18.04.2018
EE18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
NL18.04.2018
PL18.04.2018
RS18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/08]AL18.04.2018
DK18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
NL18.04.2018
PL18.04.2018
RS18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2019/03]AL18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
NL18.04.2018
PL18.04.2018
RS18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
PT20.08.2018
Former [2018/52]AL18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
NL18.04.2018
PL18.04.2018
RS18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
GR19.07.2018
Former [2018/51]AL18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
LV18.04.2018
NL18.04.2018
PL18.04.2018
RS18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
Former [2018/50]AL18.04.2018
ES18.04.2018
FI18.04.2018
HR18.04.2018
LT18.04.2018
NL18.04.2018
PL18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
Former [2018/49]AL18.04.2018
ES18.04.2018
FI18.04.2018
LT18.04.2018
NL18.04.2018
PL18.04.2018
SE18.04.2018
BG18.07.2018
NO18.07.2018
Former [2018/47]AL18.04.2018
ES18.04.2018
FI18.04.2018
LT18.04.2018
NL18.04.2018
NO18.07.2018
Former [2018/46]AL18.04.2018
LT18.04.2018
NL18.04.2018
NO18.07.2018
Former [2018/43]NL18.04.2018
Cited inInternational search[IA]US5620981  (BLANKLEY CLIFTON J [US], et al) [I] 1-20,22-25 * claim 1 * * table 1 * [A] 21;
 [IA]WO2005105097  (GPC BIOTECH AG [DE], et al) [I] 1-20,22-25 * claim 1 * * page 31, lines 20-24 * [A] 21;
 [A]WO2008150260  (GPC BIOTECH INC [US], et al) [A] 1-25 * compound 96 ** claim 1 *
by applicantUS4107288
 US5145684
    - CANCER RES, vol. 64, pages 40 - 47
    - KEATS, J.J., "Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma", LEUK LYMPHOMA, (2006), vol. 47, pages 2289 - 2300
    - BILLEREY, C. ET AL., "Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors", AM JPATHOL, (2001), vol. 158, pages 1955 - 1959
    - WILLIAMS, S. V.; HURST, C. D.; KNOWLES, M. A., "Oncogenic FGFR3 gene fusions in bladder cancer.", HUMAN MOLECULAR GENETICS, (2013), vol. 22, doi:doi:10.1093/hmg/dds486, pages 795 - 803, XP055128302

DOI:   http://dx.doi.org/10.1093/hmg/dds486
    - POLLOCK, P.M. ET AL., "Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes", ONCOGENE, (2007), vol. 26, doi:doi:10.1038/sj.onc.1210529, pages 7158 - 7162, XP008119360

DOI:   http://dx.doi.org/10.1038/sj.onc.1210529
    - JANG, J.H., "Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.", CANCER RES, (2001), vol. 61, pages 3541 - 3543
    - SAHADEVAN, K., D, "Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.", JPATHOL, (2007), vol. 213, pages 82 - 90
    - HANADA K ET AL., "Identification of fibroblast growth factor-5 as an overexpressed anti-gen in multiple human adenocarcinomas", CANCER RES, (2001), vol. 61, pages 5511 - 6
    - ARAI, Y. ET AL., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", HEPATOLOGY, (2014), vol. 59, doi:doi:10.1002/hep.26890, pages 1427 - 1434, XP055215548

DOI:   http://dx.doi.org/10.1002/hep.26890
    - BORAD, M. J. ET AL., "Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS genetics 10, e1004135) and glioblastoma (see Rand V., et. al. Sequence survey of receptor tyrosine kinases reveals mutations in gliobla", PROC NATL ACAD SCI U S A, (2014), vol. 102, pages 14344 - 9
    - PARKER, "Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours", THE JOURNAL OF PATHOLOGY, (2014), vol. 232, pages 4 - 15
    - JACKSON, C. C.; MEDEIROS, L. J.; MIRANDA, R. N., "8pl 1 myeloproliferative syndrome: a review.", HUMAN PATHOLOGY, (2010), vol. 41, pages 461 - 476, XP026975482
    - HARADA, D., "FGFR3-related dwarfism and cell signaling.", J BONE MINER METAB, (2009), vol. 27, pages 9 - 15, XP019660765
    - BELLUS, G.A., "Achondroplasia is defined by recurrent G380R mutations of FGFR3", AM JHUM GENET, (1995), vol. 56, pages 368 - 373
    - BELLUS, G.A., "A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia", NAT GENET, (1995), vol. 10, pages 357 - 359
    - ROUSSEAU, F., "Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia", NATURE, (1994), vol. 371, doi:doi:10.1038/371252a0, pages 252 - 254, XP002071230

DOI:   http://dx.doi.org/10.1038/371252a0
    - PRINOS, P., "A common FGFR3 gene mutation in hypochondroplasia", HUM MOL GENET, (1995), vol. 4, doi:doi:10.1093/hmg/4.11.2097, pages 2097 - 2101, XP009185714

DOI:   http://dx.doi.org/10.1093/hmg/4.11.2097
    - MUENKE, M. ET AL., "A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome.", AM JHUM GENET, (1997), vol. 60, pages 555 - 564
    - BELLUS, G.A. ET AL., "Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.", AM JMED GENET, (1999), vol. 85, pages 53 - 65
    - TAVORMINA, P.L. ET AL., "A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene", AM J HUM GENET, (1999), vol. 64, pages 722 - 731
    - D'AVIS, P.Y., "Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.", CELL GROWTH DIFFER, (1998), vol. 9, pages 71 - 78
    - KITOH, H., "Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online", HUM MUTAT, (1998), vol. 12, pages 362 - 363
    - TAVORMINA, P.L., "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3", NAT GENET, (1995), vol. 9, pages 321 - 328
    - BRODIE, S.G., "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations", AM JMED GENET, (1999), vol. 84, pages 476 - 480
    - CAPPELLEN, D., "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.", NAT GENET, (1999), vol. 23, doi:doi:10.1038/12615, pages 18 - 20, XP002181676

DOI:   http://dx.doi.org/10.1038/12615
    - SHUKLA, N., "Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways", CLIN CANCER RES, vol. 18, pages 748 - 757
    - MARSHALL, A.D., "PAX3-FOXO and FGFR4 in alveolar rhabdomyosarcoma.", MOL CARCINOG, vol. 51, pages 807 - 815
    - Fieser and Fieser's Reagents for Organic Synthesis, JOHN WILEY AND SONS, (1991), vol. 1-17
    - Rodd's Chemistry of Carbon Compounds, ELSEVIER SCIENCE PUBLISHERS, (1989), vol. 1-5
    - Organic Reactions, JOHN WILEY AND SONS, (1991), vol. 1-40
    - March's Advanced Organic Chemistry, JOHN WILEY AND SONS
    - LAHI, DAVID W.; ESPENSON, JAMES H, "Oxidation of Sulfoxides by Hydrogen Peroxide, Catalyzed by Methyltrioxorhenium(VII", INORG. CHEM, (2000), vol. 39, no. 10, pages 2164 - 2167
    - "Rhenium oxo complexes in catalytic oxidations", CATAL. TODAY, (2000), vol. 55, no. 4, pages 317 - 363
    - COPERET, CHRISTOPHE; ADOLFSSON, HANS; KHUONG, TINH-ALFREDO V.; YUDIN, ANDREI K.; SHARPLESS, K. BARRY, "A Simple and Efficient Method for the Preparation of Pyridine N-Oxides", J. ORG. CHEM., (1998), vol. 63, no. 5, pages 1740 - 1741
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.